Physician profile
Ryan M Trowbridge
NPI 1770996191
$6,537.30
in general payments reported to CMS, 2019-2025
33 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $163 · 2021: $227 · 2022: $1,204 · 2023: $1,254 · 2024: $1,565 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,581 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,581.23 |
| Education | $362.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,252.21 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $852.78 | 2021-2025 | Skyrizi, Rinvoq, Viberzi |
| Lilly USA, LLC | $682.86 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $598.63 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $457.08 | 2022-2025 | |
| Amgen INC. | $433.88 | 2020-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $358.16 | 2021-2025 | |
| Ucb, INC. | $321.97 | 2021-2025 | Bimzelx |
| Incyte Corporation | $264.21 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $148.81 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $110.63 | 2023-2025 | Dupixent |
| Genzyme Corporation | $110.15 | 2021-2024 | |
| Novo Nordisk INC | $99.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sandoz INC. | $98.63 | 2024 | Hyrimoz |
| Hologic Sales and Service, LLC | $95.97 | 2024 | Trident Specimen Radiography System, Trunode |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $77.90 | 2024-2025 | Purified Cortrophin Gel |
| Dermavant Sciences, INC. | $72.65 | 2023-2024 | Vtama |
| Leo Pharma INC. | $57.74 | 2022-2025 | Adbry |
| Organon LLC | $56.10 | 2024-2025 | Vtama |
| Galderma Laboratories, L.P. | $49.91 | 2022-2025 | Aklief, Nemluvio |
| Aurinia Pharma U.S., INC. | $43.51 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.76 | 2021-2023 | Cyltezo |
| Botanix Sb INC | $31.74 | 2025 | Sofdra |
| Esperion Therapeutics, INC. | $29.36 | 2023 | Nexletol |
| Kyowa Kirin, INC. | $28.73 | 2021-2023 | Crysvita |
| Kiniksa Pharmaceuticals, LTD. | $27.81 | 2023 | Arcalyst |
| Genentech USA, INC. | $27.22 | 2023 | Actemra |
| Krystal Biotech INC | $23.92 | 2025 | Vyjuvek |
| Teva Pharmaceuticals USA, INC. | $23.80 | 2022 | |
| Glaxosmithkline, LLC. | $18.65 | 2023 | Benlysta |
| Arcutis Biotherapeutics, INC. | $16.21 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $14.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.20 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Trowbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.